ClinicalTrials.gg
RecruitingNCT06041997Updated Oct 8, 2026

Smartphone Use Restriction as Treatment of Primary Headache

An interventional study of Smartphone restriction in Headache Disorders, sponsored by All India Institute of Medical Sciences. Recruiting at 1 site in India. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-08.

Sponsored by All India Institute of Medical Sciences · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Started Oct 2023; still recruiting 3 years 1 month later.
Updated Oct 8, 2026Study completion movedSponsor changed+2 moreGo to Updates ↓
Phase
Not applicable
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

The goal of this clinical trial is to study smartphone use restriction as a treatment modality in patients of primary headache. The main question[s] it aims to answer are:

  1. In patients with primary headache, does restriction of smartphone use lead to reduced consumption of medications (acute, prophylaxis, either or both)?
  2. In patients with primary headache, does restriction of smartphone use lead to better responsiveness to medications (acute, prophylaxis, either or both)?
  3. Can reduction of smartphone duration be used as a non-pharmacological treatment of primary headache?
  4. In patients with primary headache, is the type of smartphone use (phone calls, internet browsing, watching screen) determinant of the severity of headache?
  5. Can we make an addiction score to predict which patient should be advised to limit smartphone use based on the above information?
  6. In patients with primary headache, does restriction of smartphone use led to improvement in headache severity (frequency, intensity, duration, one of them or all).

The smartphone users may further be classified into low and high smartphone users depending upon the smartphone addiction questionnaire (SAQ) (appendix 1) usage score. SUs with 0-1 score on the SAQ were further grouped into low SUs, and patients with score ≥1 were grouped into high SUs. To create a homogenous group, only patients with high SU will be randomized to standard treatment (Arm C) and intervention group (Arm D).

Participants will be asked about their smartphone usage, and if found eligible, there will be a run-in period of 4 weeks after which they will be randomized to the intervention (smartphone restriction) or comparison group (no restriction recommended)

Read the detailed description

Study description:

Patients/participants:

  1. Patients ≥18 years of age
  2. Diagnosis of primary headache as per the ICHD3Beta classification ("ICHD-3 The International Classification of Headache Disorders 3rd Edition" n.d.)
  3. Willing and consenting to participate in the study. Patients will be first asked about their smartphone use.

    • If they do not use smartphone, they will be asked if they use any phone at all for calling, and their call durations will be recorded over the run-in and study period.
    • If they do not use any phone, they will fall in the external control group (Arm A).
    • If the patient uses a feature phone, but not a smartphone, he/she will be in another external control group (Arm B). These patients will not be randomized, but will be maintained on routine follow-up.
    • If they use smartphone their use will be recorded over the study period in terms of:

      o Screen use: Social network/testing/gaming/surfing/reading/music/video

    • The smartphone users may further be classified into low and high smartphone users depending upon the smartphone addiction questionnaire (SAQ): usage score. SUs with 0-1 score on the SAQ were further grouped into low SUs, and patients with score ≥1 were grouped into high SUs. To create a homogenous group, only patients with high SU will be randomized to standard treatment (Arm C) and smartphone restriction group (Arm D).

Patients with headache with history of high smartphone use will be randomized into restriction and no-restriction arm.

Restriction method:

In the 'run-in' period of four weeks, the smartphone usage will be assessed in terms of number of overall use. The patients will then be advised to cut down the usage by one-third in terms of usage hours. The compliance will be checked at the time of outcome assessment.

Comparison:

In the non-intervention group only the smartphone usage data will be collected in the study period. The non-smartphone users will be as another control arm.

Outcome:

Primary:

The number of times the patient is using acute pain medications for headache per month, within three months after initiation of study period.

Secondary:

  1. The frequency of headache over a period of one month, three months after the initiation of study period in the intervention versus control group.
  2. The number of prophylaxis medications being taken three months after the initiation of study period in the intervention versus control group.

Timeline of measuring outcome:

The follow up will be over a period of 20 weeks after screening eligibility and 16 weeks after randomization. The patient will maintain a headache diary in which he/she will enter the number of times they needed to take rescue medication.

02

Conditions studied

  • Headache Disorders

Browse trials for

03

In context

Headache Disorders

145 studies on the registry are indexed under Headache Disorders; 37 are open to participants now.

This study's planned enrollment of 60 is close to the median of 60 across 98 interventional studies indexed under Headache Disorders.

Browse Headache Disorders studies →

Lead sponsor

All India Institute of Medical Sciences is the lead sponsor of 27 studies on the registry; 18 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patients ≥18 years of age
  2. Diagnosis of primary headache as per the ICHD3Beta classification ("ICHD-3 The International Classification of Headache Disorders 3rd Edition" n.d.)
  3. Willing and consenting to participate in the study.

Exclusion criteria

Exclusion Criteria:

  • 1. Secondary headaches 2. Not consenting for participation or follow up
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
60 participants (estimated)

Study arms

  • Experimental
    Smartphone restriction

    Patients with headache with history of high smartphone use will be randomized into restriction and no-restriction arm. Restriction method: In the 'run-in' period of four weeks, the smartphone usage will be assessed in terms of number of overall use. The patients will then be advised to cut down the usage by one-third in terms of usage hours. The compliance will be checked at the time of outcome assessment.

    Behavioral: Smartphone restriction

  • No intervention
    Control

    Comparison: In the 'run-in' period of four weeks, the smartphone usage will be assessed in terms of number of overall use. In the non-intervention group only the smartphone usage data will be collected in the study period. The non-smartphone users will be as another control arm.

Interventions

  • BehavioralSmartphone restriction

    The patients will then be advised to cut down the usage by one-third in terms of usage hours. The compliance will be checked at the time of outcome assessment.

06

What researchers measure

Primary outcomes

  1. The pill burden for abortive treatment

    The number of times the patient is using acute pain medications for headache in one month

    Time frame: three months after initiation of study period

Secondary outcomes

  1. Headache frequency

    The frequency of headache over a period of one month, three months after the initiation of study period in the intervention versus control group.

    Time frame: One and three months

  2. Number of prophylactic medication

    The number of prophylaxis medications being taken three months after the initiation of study period in the intervention versus control group.

    Time frame: Three months

07

Study locations

1 of 1 sites recruiting
  • Deepti Vibha
    New Delhi, National Capital Territory of Delhi 110029, India
    Recruiting
08

References and documents

Individual participant data

Plan to share: Yes — Anonymized data will be shared on reasonable request

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: After the completion of the publication for six months

Access criteria: Shared on individual request

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2023 (actual). Primary completion is estimated for Sep 2026, 35 months after the start.

Of 41 non-industry interventional studies with no phase under Headache Disorders, half reached primary completion within 20 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 42. This study's planned 35 months is above that.

Counting every sponsor, half of 43 studies reached it within 20 months; a quarter within 7 and three quarters within 42.

Completion moved once since we started tracking on Sep 25, 2026: Nov 2026 → Dec 2026, on Oct 8, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Sep 12, 2023
First posted
Sep 18, 2023
StartActual
Oct 1, 2023
Primary completionEst.
Sep 30, 2026
CompletionEst.
Dec 30, 2026was Nov 2026
Last update
Oct 8, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
1 site added, 1 site removed
Show site
  • Deepti Vibha · New Delhi, India
Show 1 removed
  • Deepti Vibha · New Delhi, India
Oct 8, 2026
Study completion
Nov 30, 2026→Dec 30, 2026
Oct 8, 2026
Sponsor
All India Institute of Medical Sciences, New Delhi→All India Institute of Medical Sciences
Oct 8, 2026
Show all 1 update
  1. Oct 8, 2026
    1 site added, 1 site removed
    Show site
    • Deepti Vibha · New Delhi, India
    Show 1 removed
    • Deepti Vibha · New Delhi, India
    Study completion Nov 30, 2026→Dec 30, 2026
    Sponsor All India Institute of Medical Sciences, New Delhi→All India Institute of Medical Sciences
    + 5 other changes: index terms, identifiers, verification date, criteria formatting and contact details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06041997
Lead sponsor
All India Institute of Medical Sciences
Collaborators
Council of Scientific and Industrial Research, India
Responsible party
Deepti Vibha (Clinical Professor, All India Institute of Medical Sciences) — Principal investigator
First posted
Sep 18, 2023
Start date
Oct 1, 2023
Primary completion
Sep 30, 2026 (estimated)
Completion
Dec 30, 2026 (estimated)
Last update
Oct 8, 2026

Study contacts

Deepti Vibha
Contact
deeptivibha@aiims.edu
+911126594485
Rajesh Singh
Contact
+911126594049
Deepti Vibha
principal investigator · All India Institute of Medical Sciences

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion